YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to…
(RTTNews) - Pulmatrix Inc. (PULM), a clinical-stage biopharmaceutical company, on Thursday announced that it has entered into a definitive agreement to acquire Eos Senolytix Inc. in a merger transaction, alongside $19 million in concurrent…
Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader and degrader antibody conjugate therapies…
* Pulmatrix press release [https://seekingalpha.com/pr/20191009-pulmatrix-announces-second-quarter-2025-financial-results-and-divestment-plan-for-inhalation] (NASDAQ:PULM [https://seekingalpha.com/symbol/PULM]): Q2 GAAP EPS of -$0.42. * Th…
The list, released on Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.
The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.
LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iS…
Pulmatrix Inc (NASDAQ: PULM) will regain full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, following Johnsons & Johnson's (NYSE: JNJ) Enterprise Innovation's decision to terminate the license agreemen…
LEXINGTON, MA--(Marketwired - Dec 20, 2016) - CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today released an interview [http://ceocfointerviews.com/interviews/Pulmatrix16-Dece…
ADVISORY, Dec. 22, 2015 (GLOBE NEWSWIRE) -- What: Pulmatrix, Inc. (Nasdaq:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease, will visit the Nasdaq MarketSite in T…